Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided assessment states the thyroid C-cell tumor/MTC boxed-warning–related contraindication and counseling content are supported by label sections 4 and 5.1, and that rodent thyroid C-cell tumor findings are supported by section 13.1. No contradictions to the supplied label excerpts are identified.
Category Scores
Accurate Statements
Label supports a dose- and treatment-duration-dependent increase in thyroid C-cell tumors in mice and rats, and it is unknown whether OZEMPIC causes thyroid C-cell tumors (including MTC) in humans (Section 5.1).
5.1 Risk of Thyroid C-Cell Tumors: rodent dose/duration-dependent increase; uncertainty in humans.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2 (Section 4).
4 CONTRAINDICATIONS: contraindicated in patients with personal/family history of MTC or MEN 2.
The label instructs counseling patients about potential risk for MTC and that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value (Section 5.1).
5.1: counsel regarding potential risk and notes uncertain value of routine monitoring; also describes further evaluation if elevated calcitonin or nodules are present.
Carcinogenesis study results in nonclinical toxicology show statistically significant increases in thyroid C-cell adenomas and numerical increases in carcinomas at clinically relevant exposures (Section 13.1).
13.1 Carcinogenesis/Mutagenesis: CD-1 mice and Sprague Dawley rats findings consistent with statement.
Unsupported Statements
“Boxed Warning ‘Risk of Thyroid C-Cell Tumors.’” (as a claim of boxed-warning presence).
The prompt indicates excerpts are consistent with the boxed warning, but the provided label excerpts do not explicitly show the boxed-warning text itself. Based on the supplied excerpts, contraindications and Warnings/Precautions 5.1 are verifiably supported, but the boxed-warning text is not directly quoted in the excerpt set.
Contradictions
Important Omissions
No evaluation is provided for any specific contraindication details beyond personal/family history of MTC and MEN 2 (e.g., the hypersensitivity contraindication).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The assessment concerns label alignment for thyroid C-cell tumor risk, and the key contraindication/counseling and tumor-risk statements are supported by the provided label excerpts. Only the explicit boxed-warning text is not directly evidenced in the quoted excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Boxed-warning presence was not directly quoted/verified from the excerpt set.
Suggested Improvement
Quote or explicitly reference the boxed-warning text from the label (if available) to directly support the boxed-warning statement; optionally also include verification of the hypersensitivity contraindication if assessing contraindications more comprehensively.